


CHC Healthcare Group (4164TT) 2025 1st Investor Conference

2025/06/23

- This document is provided by CHC Healthcare Group (CHC). Information contained in this document has not been audited or reviewed by any accountants or independent experts. CHC makes no express or implied representations or warranties as to the fairness, accuracy, completeness, or correctness of such information or opinions.
- This document is provided as of the date herein and will not be updated to reflect any changes hereafter. CHC, its affiliates and their representatives do not accept any responsibility or liability for any damage caused by their negligence or any other reasons, nor do they accept responsibility or liability for any loss or damages arising from the use of this document or the information contained herein or anything related to this document.
- This document may contain forward-looking statements, including but not limited to all statements that address activities, events or developments that CHC expects or anticipates to take place in the future based on the projections of CHC toward the future, and various factors and uncertainty beyond CHC's control. Therefore, the actual results may differ materially from those contained in the forward-looking statements.
- This document is not and cannot be construed as an offer to purchase or sell securities or other financial products or solicitation of an offer.
- This document may not be directly or indirectly reproduced, redistributed or forwarded to any other person and may not be published in whole or in part for any purpose.




**Company
Overview**

**Business
Results**

**Latest
Updates**

**Future
Guidance**



**Company
Overview**

**Business
Results**

**Latest
Updates**


**Future
Guidance**

Basic Information


- **Company name:** CHC Healthcare Group
- **Company code:** 4164 TT
- **Date of establishment:** 2009/11/27
(1st subsidiary, Chiu Ho Instruments & Reagents, was founded in 1977)
- **Chairman:** Mr. Pei-Lin, Lee
- **Headquarters :** Taipei
- **Branches :** Taichung, Kaohsiung, Guangzhou, Beijing, Shenyang, Jakarta, London
- **Paid-in capital:** NT\$ 1,846,488,710
- **Date of listing:** 2012/10/24




Milestones



Business Scope




Medical Equipment Distribution



Medical Management Service



Led by TW medical authorities
Manufacturer certified team
Nearly 100 engineers trained



Diversification of Business - Chain Pharmacies Channel



- Community chain pharmacies
- Comprehensive products & professional consulting service
- Health care for all ages

 **Everyone's Good Neighbor**



Prescription Medicine



Aesthetic Medicine



Weight Management



Baby Essentials



Elderly Supplies



LTC 2.0 Service

Diversification of Business - Irradiation Service

SAFE



PRECISE



ECO-FRIENDLY



SUSTAINABILITY


30% of energy savings

EFFICIENT



STABLE





**Company
Overview**


**Business
Results**

**Latest
Updates**


**Future
Guidance**

Operating Revenue


Operating revenue
(NT\$ thousand)



Product Mix





Profitability



Earnings Distribution

	Cash dividends per share (NT\$)	Basic EPS (NT\$)	Payout ratio
2020	2.01	2.53	79%
2021	2.011	2.43	83%
2022	2.01	2.21	91%
2023	2.01	2.55	79%
2024	1.51	1.01	150%





**Company
Overview**

**Business
Results**

**Latest
Updates**

**Future
Guidance**

Precision Medicine - Versa HD® & Harmony



Elekta

Precision Medicine - Elekta MR Linac




Elekta

Elekta Unity

Two worlds,
one future.

Precision Medicine - IBA Proton Therapy



40⁺% MARKET SHARE

IN PROTON THERAPY

75⁺ PROTON CENTERS

POWERED BY IBA

130,000⁺ PATIENTS

TREATED ON IBA EQUIPMENT

Precision Medicine - Baxter Integrated Solution in da Vinci Surgery


Baxter



Precision Medicine – BVI Trifocal Hydrophobic Toric IOL




Health Industry - Chain Pharmacies Channel





Irradiation Business - Workflow


Irradiation Process (E-Beam & X-Ray)



Laboratory Testing







**Company
Overview**

**Business
Results**

**Latest
Updates**

**Future
Guidance**

Elekta Evo




Adapt at your rhythm



The only CT-Linac that uniquely evolves on your terms and offers everything from the everyday to the extraordinary.



BNCT - Neutron Therapeutics



BNCT - Neutron Therapeutics

Neutron Therapeutics and Helsinki University Hospital Treat First Head and Neck Cancer Patients Using Accelerator-Based Boron Neutron Capture Therapy

- *First clinical application of accelerator-based boron neutron capture therapy outside of Asia*
- *Ongoing clinical trial is enrolling patients with inoperable, locally recurrent head and neck cancer*

May 16, 2025 – HELSINKI, FINLAND and BOSTON, MA – Neutron Therapeutics LLC and the Helsinki University Hospital announce that they have treated the first cancer patients in a European hospital with accelerator-based boron neutron capture therapy (BNCT). This milestone marks the culmination of a multi-year collaborative effort and represents the first clinical application of accelerator-based BNCT in the west.

Approved in Japan but not currently available to patients outside of Asia, BNCT is a tumor-targeted radiation therapy in which epithermal neutrons activate a boron-bearing compound that is selectively taken up by tumors. The boron-neutron reaction generates high-energy alpha particles within tumor cells, destroying them while sparing healthy tissues. In contrast to treatments like traditional radiation or chemotherapy, BNCT is administered in just one or two sessions and has the potential to deliver highly effective radiation therapy at the cellular level while causing minimal disruption to patient quality of life.

The patients treated are the first in a ten-patient study aimed at demonstrating the safety of BNCT for locally recurrent head and neck cancer using Neutron Therapeutics' nuBeam® device, a compact accelerator-based, high-throughput neutron source used in combination with a locally compounded boron-carrying drug. The Comprehensive Cancer Center at Helsinki University Hospital has served as a hub for BNCT research and clinical trials since 1992 and is the first European facility to house a nuBeam® Suite.

Neutron Therapeutics' nuBeam® Suite includes the complete array of tools required to administer BNCT: a neutron source, patient positioning & imaging capabilities, treatment control software, and treatment planning software. Clinical validation of the nuBeam® Suite is ongoing and the company intends to submit for a CE mark when complete. Neutron Therapeutics is also in discussions with academic medical centers in the United States to bring this innovative cancer therapy to American patients.



First Case in Europe

In May 2025, U.S.-based Neutron Therapeutics conducted clinical treatment using accelerator-based BNCT at Helsinki University Hospital (HUS) in Finland.


PRESS RELEASE - PUBLISHED ON 16.5.2025, 08:31

BNCT treatments for cancer patients have started as part of a clinical trial

BNCT | CANCER | RADIATION THERAPY

HUS has introduced the first in-hospital boron neutron capture therapy accelerator in Western countries. Boron neutron capture therapy, BNCT for short, is a radiation therapy method that can destroy cancer cells while sparing the surrounding tissue.

BNCT - Neutron Therapeutics



neutron
therapeutics

HUS Helsinki University Hospital

Applications of Irradiation




- Bacteria elimination
- Germination inhibition
- Shelf life extension




- Bioburden reduction
- Sterility assurance
- Infection risk avoidance



- Crosslinking
- Material modification
- Resistance reinforcement



- Semi-conductors switching-time improvement
- Aerospace material resistance testing
- Gemstone color enhancement
- Postal mail decontamination...



Elderly Care Business

Taiwan + Japan

< Integrating Elderly & Medical Care >

Day care center

(approx. 100 cases)

+ Residential institution

(approx. 300 beds)

+ Orthopedic rehabilitation hospital

(approx. 100 beds)



3D Sketch

Thank you!



www.chcg.com

Copyright © 2019 CHC Limited. All rights reserved.